Loading stock data…
EOLS
$5.33-0.06 (-1.11%)
Market ClosedLast close May 1
Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Evolus, Inc. in the Healthcare sector is trading at $5.33. The stock is currently near its 52-week low of $3.86, remaining 13.3% below its 200-day moving average. Technical signals show overbought RSI of 75 and bullish MACD crossover, explaining why EOLS maintains its current current market pressure. The Whystock Score of 30/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Overbought levels (RSI 75) — risk of consolidation or pullback
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$5.33
Potential Upside
5%
Whystock Fair Value$5.60
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus6 analysts
Mean target$14.67+175.2%
Range$10.00 – $20.00
Fundamentals
Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the te...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$337.66M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
1.00
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
268.31%
Volume
Today's trading volume
407,164
Recent News
How The Evolus (EOLS) Story Is Shifting As Analysts Reset Growth And Valuation Assumptions
Evolus is back in focus after analysts revisited their price target framework, keeping the fair value unchanged at $14.67 per share. Some see the maintained target as confirmation that the core thesis is intact, while others read the previous $4 cut as a sign that expectations around long term revenue may have been reset. As you read on, you will see how to interpret this evolving analyst narrative and what to watch if you are tracking Evolus from here. Analyst Price Targets don't always...
April 2026's Leading Growth Stocks With Insider Confidence
The United States market has shown robust performance, rising 3.4% over the last week and an impressive 35% over the past year, with earnings expected to grow by 16% annually. In such a thriving environment, growth companies with high insider ownership can be particularly appealing as they often indicate strong confidence from those closest to the business.
Evolus Targets Double-Digit Growth, Full-Year Profitability at Needham Healthcare Conference
Evolus (NASDAQ:EOLS) executives told investors at Needham & Company’s 25th Annual Healthcare Conference that the company is pursuing double-digit growth and a transition to full-year profitability as it expands beyond its flagship neurotoxin Jeuveau and scales its newer hyaluronic acid (HA) fill
How The Evolus (EOLS) Investment Story Is Shifting After Softer Guidance And Target Cuts
The latest analyst work on Evolus keeps the modeled fair value steady at US$14.67 per share, even as several firms reduce their published price targets. Those cuts are tied less to a change in the core valuation inputs and more to how analysts interpret the softer preliminary 2025 net revenue outlook, the 2026 guide, and the scaled back long term narrative. As you read on, you will see how to approach this evolving setup and what to watch as the story continues to develop. Stay updated as the...
Revance CEO Nadeem Moiz on Expansion, Opportunities & Capitalization
By Karen Roman Exec Edge sat down with Nadeem Moiz, Chief Executive Officer at Revance, to learn more about the company’s vision in aesthetics, skincare and therapeutics. Exec Edge: Tell us about Revance and the science-powered products within your portfolio across aesthetics, skincare and therapeutics. At Revance we believe that science based innovative products drive […]